ACCESS Newswire
01 Aug 2022, 17:31 GMT+10
Both bills eliminate researchers from obtaining any marijuana products from any state dispensaries or growers.
WESTERLY, RI / ACCESSWIRE / August 1, 2022 / MMJ International Holdings, MMJ BioPharma Labs, and MMJ BioPharma Cultivation the premier medical cannabis research companies announced that it has completed the FDA required manufacturing of its proprietary THC and CBD marijuana soft gelatin capsule. MMJ International Holdings has several filings with the FDA in Multiple Sclerosis and Huntington's disease and is developing a non-synthetic oral drug product from the marijuana plant extracts. MMJ will be utilizing its new product for its clinical trials once FDA approved.
MMJ had received a DEA permit to import its cannabis proprietary extracts into the United States to develop therapies for Huntington's Disease and Multiple Sclerosis. After a considerable amount of work, the team has reach several milestones by developing its proprietary scientific extraction process of THC, CBD, and other ingredients for its drug formulation. MMJ was awarded the coveted FDA Orphan award for Huntington's disease and MMJ BioPharma Labs has been awarded their DEA cannabis schedule 1 analytical lab registration.
While MMJ has been cooperating with multiple government agencies, including FDA, DEA, U.S. Customs and Border Protection (CBP), Health Canada, and the Center for Drug Evaluation and Research (CDER), to accomplish its mission most recently it was forced to file suit against the DEA for dragging their feet. Duane Boise the President and Founder stated ' Unfortunately we had to file suit against the DEA to facilitate a response however we are in discussion to clarify any concerns the DEA may have. We feel confident that the API Bulk Manufacturing registration will be issued soon. The DEA is currently processing the company's application so it can proceed with the FDA required evaluation and research'.
Tim Moynahan, the companies chairman opined ' it is egregiously wrong that the DEA has taken so long to process our application. We have been patient since December of 2018 waiting for the DEA to act. We recognize that there is significant public interest in cannabis and cannabis-derived compounds; however, we must work with the FDA and DEA to fill in the knowledge gaps about the science safety and quality of MMJ's products. We are committed to advancing our product development through an approach that is in line with the governments mission to prioritizes public health, fosters innovation, and promotes consumer confidence.
The DEA has stated, ' the DEA anticipates that additional strains of marihuana will be produced and made available to researchers. This should facilitate research, advance scientific understanding about the effects of marihuana, and potentially aid in the development of safe and effective drug products that may be approved for marketing by the Food and Drug Administration,'
Dr Elio Mariani, the CEO stated, 'MMJ's clinical trials will provide patient dosing, safety, and efficacy data to the FDA to prove that cannabis can treat the debilitating effects of Multiple Sclerosis and Huntington's Disease. MMJ continues its process of scientific drug development and discovery by following the FDA development processes and the DEA regulatory manufacturing guidelines.
This past week the U.S. House of Representatives passed a revised bipartisan bill that would make it easier for researchers to study marijuana. The bill passed Tuesday by a resounding vote of 325-95. The Medical Marijuana and Cannabidiol Research Act, or H.R. 8454, now goes to the Senate, where it is expected to pass.
Both bills eliminate researchers from obtaining any marijuana products from any state dispensaries or growers.
Researchers can only obtain product for research from DEA approved schedule 1 registrants.
CONTACT:
Sara Parker
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
Get a daily dose of Miami Mirror news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Miami Mirror.
More InformationTOKYO, Japan: Toyota is weighing plans to build the next-generation RAV4 SUV in the United States, according to three people familiar...
WASHINGTON, D.C.: Ford is recalling more than 148,000 vehicles across two safety campaigns, according to a notice issued by the National...
NEW YORK CITY, New York: Archer Aviation has announced plans to start an air-taxi service in New York City, working with United Airlines....
TAIPEI, Taiwan: Taiwan's TSMC reported stronger-than-expected first-quarter earnings on Thursday, driven by booming demand for AI-related...
LONDON - Google is facing a multibillion-pound legal challenge in the UK over allegations it misused its dominance in online search...
Lyft is making its first move into Europe with the purchase of mobility platform FreeNow, a nearly $200 million deal that signals a...
THE VATICAN - The world is in shock and mourning on Easter Monday as it woke to the news that Pope Francis had died. Having recently...
NEW YORK CITY, New York: A former New York City police sergeant, Michael McMahon, was sentenced this week to 1.5 years in prison. He...
WASHINGTON, D.C.: U.S. Interior Secretary Doug Burgum has ordered a stop to construction of Equinor's Empire Wind project off New York's...
SINGAPORE: Amid rising trade tensions, several Asian nations are stepping up energy purchases from the U.S. in hopes of easing tariff...
WASHINGTON DC - In a bid to combat illegal border crossings, the Trump Administration has enacted an emergency transfer of some 110,000...
More than 200 journalists and news photographers, together with family members, have been killed in Gaza in the last 16 months. Despite...